Abstract
The clinical efficacy and safety of cefluprenam (CFLP), a newly developed cephalosporin antibiotic, on infections associated with hematologic disorders were investigated in 1 patient with sepsis, 4 with sepsis suspected, 3 with acute pharyngitis, 1 with acute bronchitis and 1 with bronchopneumonia. CFLP was administered by intravenous drip infusion at a dose of 1.0 or 2.0 g twice a day for 6-19 days. Clinical responses were excellent in 4, good in 1, fair in 1 and poor in 2 cases. Skin rash was observed in 1 patient. Abnormal laboratory findings were observed in 2 patients.
